Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2025 (Q3 2025)
Business Overview: Henry Schein is a global provider of health care products and services to office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $3,339 million | $3,174 million | $9,747 million | $9,482 million |
| Gross Profit | $1,026 million | $993 million | $3,042 million | $3,023 million |
| Gross Margin | 30.7% | 31.3% | 31.2% | 31.9% |
| Operating Income | $164 million | $157 million | $490 million | $466 million |
| Net Income (Total) | $109 million | $99 million | $316 million | $302 million |
| Net Income (Attributable to HSIC) | $101 million | $99 million | $297 million | $296 million |
| Diluted EPS | $0.84 | $0.78 | $2.42 | $2.30 |
| Operating Cash Flow (YTD) | $331 million | $644 million | - | - |
| Total Debt | $3,096 million | $2,536 million | - | - |
| Cash & Equivalents | $136 million | $122 million | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.2% in Q3 2025 and 2.8% YTD 2025 compared to the prior year periods. Growth was driven by internal organic growth, acquisitions, and favorable foreign exchange impacts.
- Segment Performance:
- Global Distribution: Sales up 4.8% (Q3) and 2.4% (YTD). Medical sales grew 4.7% (Q3) due to pharmaceutical and Home Solutions growth, partially offset by lower respiratory diagnostic demand.
- Global Specialty Products: Sales up 5.9% (Q3) and 4.0% (YTD), driven by dental implant and biomaterial growth.
- Global Technology: Sales up 9.7% (Q3) and 6.7% (YTD), driven by adoption of cloud-based practice management solutions.
- Restructuring Costs: The company recorded $34 million in restructuring charges in Q3 2025 and $82 million YTD 2025 under the "2024 Plan," compared to $48 million (Q3) and $73 million (YTD) in the prior year. These costs relate to severance, accelerated amortization, and exit costs.
- Cash Flow: Operating cash flow decreased significantly YTD 2025 ($331 million) compared to YTD 2024 ($644 million), primarily due to changes in working capital accounts (receivables, inventory, payables) and the normalization of cash collections following the 2023 cyber incident.
- Debt Levels: Total debt increased to $3.096 billion from $2.536 billion at year-end 2024, reflecting increased borrowings to fund investments and acquisitions.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Partnership: In May 2025, the company issued shares to KKR for a $250 million investment. KKR now owns approximately 14.5% of the company. In November 2025, the ownership limit was increased to 19.9%.
- Share Repurchases: The Board authorized an additional $750 million in share repurchases in September 2025. An accelerated share repurchase program of $250 million was completed in July 2025. Approximately $980 million remains available for future repurchases.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes provisions for immediate expensing of R&D and changes to international tax provisions. The company anticipates a reduction in current income tax liabilities and deferred tax assets.
- Cyber Incident: No expenses were incurred related to the October 2023 cyber incident in Q3 2025. The company received the final $20 million in insurance proceeds in Q1 2025, completing the recovery.
- Tariffs and Economic Conditions: The company notes a volatile global trade environment due to new U.S. tariffs. While not materially impacting results in the first three quarters, sales of U.S. dental equipment were temporarily impacted by market uncertainty in Q2 2025.
- Restructuring Outlook: The 2024 restructuring plan is expected to be completed by the end of 2027. The company expects to record additional charges in 2025 through 2027 but has not determined the specific amount.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the decline in operating cash flow and the specific drivers behind the increase in accounts receivable and inventory levels.
- Debt Covenants: Review the impact of increased debt levels on leverage ratios and compliance with the Revolving Credit Agreement and Term Loan covenants.
- Restructuring Execution: Monitor the progress of the 2024 restructuring plan and the timing of future cash outflows for severance and exit costs.
- KKR Partnership: Assess the long-term strategic implications of the KKR investment and the potential for future capital raises or governance changes.
- Tax Rate Volatility: Evaluate the impact of the OBBBA and global Pillar Two tax rules on future effective tax rates and cash tax liabilities.
- Acquisition Integration: Review the integration progress of recent acquisitions, particularly in the Global Specialty Products segment, and the realization of anticipated synergies.